Topics

Human medicines European public assessment report (EPAR): Mysimba, naltrexone / bupropion, Obesity,Overweight, Date of authorisation: 26/03/2015, Revision: 12, Status: Authorised

10:34 EDT 14 Aug 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Mysimba, naltrexone / bupropion, Obesity,Overweight, Date of authorisation: 26/03/2015, Revision: 12, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Mysimba, naltrexone / bupropion, Obesity,Overweight, Date of authorisation: 26/03/2015, Revision: 12, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Mysimba, naltrexone / bupropion, Obesity,Overweight, Date of authorisation: 26/03/2015, Revision: 12, Status: Authorised"

Quick Search

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Obesity
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...